Wolfram Pönisch
4PUBLICATIONS
4CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (4)
Sort by Publication Date:
|Jul 18, 2022
Reduced alpha diversity of the oral microbiome correlates with short progression-free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib-based therapy (AGMT MM 1, phase II trial).Heinz Ludwig, Bela Hausmann, Martin Schreder
|Jan 12, 2021
Prognostic impact of rapid reduction of involved free light chains in multiple myeloma patients under first-line treatment with Bendamustine, Prednisone, and Bortezomib (BPV).Tanja Holzhey, Wolfram Pönisch, Song-Yau Wang
|Aug 23, 2017
Lenalidomide in combination with bendamustine and prednisolone in relapsed/refractory multiple myeloma: results of a phase 2 clinical trial (OSHO-#077).Juliane Beck, Andreas Schwarzer, Dietrich Gläser
|May 24, 2017
Successful treatment of patients with newly diagnosed/untreated light chain multiple myeloma with a combination of bendamustine, prednisone and bortezomib (BPV).Hannah Tessenow, Madlen Holzvogt, Bruno Holzvogt
Pageof 1
